Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Modern Pathology"
DOI: 10.1038/s41379-021-00738-5
Abstract: The response of human epidermal growth factor receptor2 (HER2)- positive breast cancer (BC) patients to anti-HER2 targeted therapy is significant. However, the response is not uniform and a proportion of HER2-positive patients do not respond.… read more here.
Keywords: her2 positive; neoadjuvant treatment; response; her2 ihc ... See more keywords
Navigating the HER2 Frontier: Advancing Gastrointestinal Adenocarcinoma Diagnosis through Updated NCCN Guidelines
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqae129.101
Abstract: HER2-status is routinely tested in breast and upper-gastrointestinal (GI) cancers. Studies have shown the importance of anti-HER2 therapy with HER2 being a negative predictive marker in advanced colorectal cancer (CRC). Thus, recent NCCN-guidelines recommend screening… read more here.
Keywords: her2; pathology; her2 ihc; her2 status ... See more keywords
Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Pathology"
DOI: 10.1136/jcp-2025-210095
Abstract: Aims Fam-trastuzumab deruxtecan-nxki (T-DXd) was recently approved for advanced stage or metastatic solid tumours with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) 3+ staining. Data on HER2 IHC testing and knowledge of genomic… read more here.
Keywords: lung cancer; cytology; pathology; her2 ihc ... See more keywords
Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.advbc23-a026
Abstract: Immunohistochemistry (IHC) may not accurately measure HER2 levels and does not reflect HER2 activity/phosphorylation in HER2-negative patients in the HER2 LOW (IHC 1+/2+) and ULTRA-LOW (IHC 0) range [PMID: 35595825). Yet, accurate quantification of HER2… read more here.
Keywords: ihc; her2; quantitative her2; her2 ihc ... See more keywords
Abstract PO2-13-03: Spatial HER2 heterogeneity on HER2-PET in HER2-low and negative disease: potential biomarker for antibody-drug conjugate effect
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po2-13-03
Abstract: Background: Anti-HER2 antibody drug conjugates (ADCs) can assert an effect in part of patients with HER2-low breast cancer. In light of patient burden and financial sustainability, biomarkers to select responding patients are urgently needed, but… read more here.
Keywords: low negative; her2 low; her2 pet; her2 ... See more keywords
Abstract PO4-26-08: Prevalence of HER2-low and IHC >0 to < 1+ in breast cancer and its concordance between historical and rescored results: a multi-center, retrospective study in China
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs23-po4-26-08
Abstract: Background: With Trastuzumab deruxtecan (T-DXd) changing the anti-HER2 treatment paradigm, HER2-low (defined as IHC2+/ISH- and IHC1+) breast cancer patients have emerged as a new targetable population. The lower threshold for HER2 expression that can benefit… read more here.
Keywords: ihc; breast cancer; her2 low; her2 ... See more keywords
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.1092
Abstract: 1092 Background: HER2 status has become more important with new treatment regimens subcategorizing HER2 to into low (1+or 2+ FISH-) or absent HER2 expression. Through comprehensive genomic profiling (CGP), we aim to identify distinctive molecular… read more here.
Keywords: her2 low; her2; her2 ihc; status ... See more keywords
HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.538
Abstract: 538 Background: Bladder cancer (BC) has a relatively high rate of human epidermal growth factor receptor 2 (HER2) alterations. The association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry (IHC) expression and associations with clinical outcomes… read more here.
Keywords: ihc expression; her2; her2 ihc; bladder cancer ... See more keywords